Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
  • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
  • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
  • G01N2333/4701—Details
  • G01N2333/4709—Amyloid plaque core protein
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/28—Neurological disorders
  • G01N2800/2814—Dementia; Cognitive disorders
  • G01N2800/2821—Alzheimer

Definitions

• the present invention relates generally to methods and compositions for detecting soluble 3-amyloid peptide (/SAP) in fluid samples. More particularly, the present invention relates to screening methods for the identification of inhibitors of /3AP production where j ⁇ AP is detected in vitro or in vivo and to diagnostic methods where / SAP is detected in patient samples.
• AD Alzheimer's Disease
• AD is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that gradually leads to profound mental deterioration and ultimately death.
• AD is a very common cause of progressive mental failure (dementia) in aged humans and is believed to represent the fourth most common medical cause of death in the United States.
• AD has been observed in races and ethnic groups worldwide and presents a major present and future public health problem. The disease is currently estimated to affect about two to three million individuals in the United States alone. AD is at present incurable. No treatment that effectively prevents AD or reverses its symptoms and course is currently known.
• the brains of individuals with AD exhibit characteristic lesions termed senile (or amyloid) plaques, amyloid angiopathy (amyloid deposits in blood vessels) and neurofibrillary tangles.
• senile or amyloid
• amyloid angiopathy amyloid deposits in blood vessels
• neurofibrillary tangles Large numbers of these lesions, particularly amyloid plaques and neurofibrillary tangles, are generally found in several areas of the human brain important for memory and cognitive function in patients with AD. Smaller numbers of these lesions in a more restricted anatomical distribution are also found in the brains of most aged humans who do not have clinical AD.
• Amyloid plaques and amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCH A-D) .
• a definitive diagnosis of AD usually requires observing the aforementioned lesions in the brain tissue of patients who have died with the disease or, rarely, in small biopsied samples of brain tissue taken during an invasive neurosurgical procedure.
• amyloid angiopathy amyloid angiopathy characteristic of AD and the other disorders mentioned above is an approximately 4.2 kilodalton (kD) protein of about 39-43 amino acids designated the /3-amyloid peptide (/3AP) or sometimes A/3, A/3P or /3/A4. / SAP was first purified and a partial amino acid sequence reported in Glenner and Wong (1984) Biochem. Biophys. Res. Commun. 120:885-890. The isolation procedure and the sequence data for the first 28 amino acids are described in U.S. Patent No. 4,666,829.
• / SAP is a small fragment of a much larger precursor protein, referred to as the /3-amyloid precursor protein (APP) , that is normally produced by cells in many tissues of various animals, including humans.
• APP /3-amyloid precursor protein
• ⁇ AP arises as a peptide fragment that is cleaved from APP by as-yet-unknown enzymes (proteases) .
• proteases as-yet-unknown enzymes
• a mutation at amino acid 693 of the 770-amino acid isoform of APP has been identified as the cause of the /3AP deposition disease, HCHWA-D, and a change from alanine to glycine at amino acid 692 appears to cause a phenotype that resembles AD in some patients but HCHWA-D in others.
• the discovery, of these and other mutations in APP in genetically based cases of AD proves that alteration of APP and subsequent deposition of its /?AP fragment can cause AD.
• AD Alzheimer's disease
• SAP-related diseases there remains a need to develop methods and compositions for diagnosis and treatment of the disease(s).
• Treatment methods could advantageously be based on drugs which are capable of inhibiting the generation of jSAP in vivo.
• screening assays for potential drugs which can inhibit /3AP generation in in vivo and in vitro models.
• methods and compositions for diagnosis of /3AP-related conditions where the diagnosis is based on detection of / SAP in patient fluid samples.
• Specific assays for /3AP detection should be capable of detecting /3AP in fluid samples at very low concentrations as well as distinguishing between jSAP and other fragments of APP which may be present in the sample.
• the present invention overcomes these difficulties with the use of monoclonal antibodies specific to an epitope in the central junction region of intact / SAP.
• EP 444,856 provides a means of diagnosing Alzheimer's disease using a sandwich immunoassay to "Alzheimer's Disease Associated Protein" (ADAP) .
• ADAP is defined as a material reactive with the monoclonal antibody termed Alz50, originally described by Wolozin et al. (1986) Science 232:648-650. Alz50 has more recently been shown to react specifically with phos- phorylated forms of tau (Ksiezak-Reder et al. (1988) J. Biol. Che . 263:7943-7947; Ueda et al. (1990) J. Neuroscience
• ADAPs represent phosphorylated forms of tau and are unrelated to the amyloid precursor protein of ⁇ kP described in this invention.
• the present invention provides methods and compositions useful for the identification of / 3-amyloid peptide (/3AP) production inhibitors as well as for the diagnosis and monitoring of ⁇ AP-related conditions in patients, where the methods and compositions rely on the specific detection of soluble / SAP and/or ⁇ AP fragments in fluid samples.
• a test compound is introduced to an in vitro or in vivo ⁇ AP generation model, and the effect of the test compound on the amount of soluble ⁇ AP or ⁇ AP fragment generated by the model is observed.
• Particularly useful as an in vitro model are cell lines which express APP variants which overproduce ⁇ AP.
• Test substances which affect the production of ⁇ AP and/or ⁇ AP fragments are considered to be likely candidates for further testing for use as therapeutic drugs in the treatment of ⁇ AP-related conditions, particularly Alzheimer's Disease.
• a patient sample such as blood, cerebrospinal fluid (CSF) , urine, or peritoneal fluid
• CSF cerebrospinal fluid
• a predetermined control value such as a normal value (in the case of diagnosis) or a prior patient value (in the case of monitoring) .
• the present invention provides specific binding assays which are useful for the measurement of ⁇ AP concentrations in fluid samples and which may be employed in both the drug screening and patient diagnostic and monitoring methods just described.
• the specific binding assay of the present invention is capable of detecting soluble ⁇ AP at the very low concentrations which are characteristic of the patient fluids and conditioned culture media, typically being capable of measuring threshold concentrations in the range from about 1 ng/ml to 10 ng/ml, or lower.
• Specific binding assays employ at least one binding substance specific for an epitope or determinant site on the ⁇ AP molecule, which site is generally not found on other fragments or degradation products of the ⁇ -amyloid precursor protein (APP) .
• Particularly useful are antibodies which recognize a junction region within ⁇ AP, where the junction region is located about the site of normal proteolytic cleavage of APP between residues Lys 15 and Leu 17 (Esch et al. (1990) Science 248:492-495 and Anderson et al. (1991) Neuro. Science Lett. 128:126-128), typically spanning amino acid residues 13 and 28.
• Exemplary specific binding assays include two-site (sandwich) assays in which the capture antibody is specific for the junction region of ⁇ AP, as just described, and a labeled second antibody is specific for an epitope other than the epitope recognized by the capture antibody.
• Particularly useful are second antibodies which bind to the amino-terminal end of ⁇ AP, typically recognizing an epitope within amino acid residues 1-16.
• Fig. 1 is a graph illustrating the detection of three synthetic ⁇ AP peptides using an ELISA assay format with monoclonal antibody 266 as the capture antibody and monoclonal antibody 10D5 as the reporter antibody.
• Antibody 266 was prepared against a synthetic peptide including amino acid residues 13-28 of ⁇ AP.
• Antibody 10D5 was raised against a synthetic peptide including amino acid residues 1-28 of ⁇ AP.
• Figs. 2A and 2B are charts comparing the plasma and CSF concentrations of ⁇ AP in normal control and AD patients.
• Fig. 3 is a chart comparing the CSF concentration of ⁇ AP in normal controls (C) , Alzheimer's Disease patients (AD), cerebral vascular accident (CVA) patients (stroke) , and Parkinson's Disease (PD) patients.
• Fig. 4 is a Western blot of affinity-purified conditioned media from a cell line which overexpresses APP. The affinity-purified material from the conditioned media of human mixed-brain cell cultures which had been further purified by reversed-phase chromatography.
• Fig. 5 is an autoradiogram demonstrating the presence of soluble ⁇ AP in the culture fluid of human kidney 293 cells. The ⁇ AP was i munoprecipitated from the culture fluid with a ⁇ AP-specific antibody to residues 1-40 of ⁇ AP.
• Fig. 6 is an autoradiogram demonstrating that ⁇ AP in the media of human kidney 293 cells is fully soluble and that it remains in the post-10 5 xg supernatant and is not found in the post-10 5 xg pellet after ultracentrifugation.
• Fig. 7 shows the quantitation of ⁇ AP (left panel) and the secreted ⁇ -amyloid precursor protein (APPs) (right panel) in conditioned media in transiently transfected 293 cells using two distinct sandwich ELISAs. Each column represents the mean of four transfection experiments with normal or variant APP constructs with the exception of the mock column, which is based on three transfection experiments.
• Fig. 8 is an autoradiogram demonstrating the levels of soluble ⁇ AP in the culture fluid of human kidney 293 cells transfected with normal or variant APP 695 constructs.
• the present invention results from the discovery that detectable amounts of soluble ⁇ -amyloid peptide ( ⁇ AP) and ⁇ AP fragments are generated continuously at low concentrations by a wide variety of mammalian cells.
• ⁇ AP soluble ⁇ -amyloid peptide
• ⁇ AP fragments are generated continuously at low concentrations by a wide variety of mammalian cells.
• ⁇ AP peptides are generated in vitro by cultured mammalian cells and may be measured in the conditioned culture medium of numerous mammalian cell lines.
• ⁇ AP peptides are present in the body fluids of various mammalian hosts, and that elevated levels of ⁇ AP peptides are associated with ⁇ AP-related conditions, such as Alzheimer's Disease and Down's Syndrome.
• the present invention provides both methods for drug screening to identify potential ⁇ AP generation inhibitors and methods for diagnosing and monitoring ⁇ AP-related conditions. Both methods rely on the measurement of very low ⁇ AP concentrations in a fluid sample, typically in the range from 0.1 ng/ml to 10 ng/ml, with the present invention further providing highly sensitive and specific methods for performing such measurements.
• detection methods of the present invention provide for measurement of ⁇ AP at threshold concentrations of 0.1 ng/ml and below, and are sufficiently specific to distinguish ⁇ AP from other fragments of the ⁇ -amyloid precursor protein (APP) which contain precursor amino acids in addition to the 39-43 amino acids that comprise the ⁇ AP region.
• APP ⁇ -amyloid precursor protein
• ⁇ AP and ⁇ AP fragment generation are not presently understood. It is possible that intact or full length ⁇ AP is produced intracellularly and thereafter released or secreted into the extracellular fluid, i.e., body fluids in vivo and conditioned cell culture medium in vitro .
• a precursor protein or fragment which may be the entire APP or a portion thereof containing the ⁇ AP region, is secreted or released from the mammalian cells and processed outside of the cellular source.
• the present invention relies on the detection and measurement of the concentrations or amounts of ⁇ AP and ⁇ AP fragments in extracellular fluids, including conditioned culture medium and body fluids, as discussed in more detail below.
• ⁇ -amyloid peptide refers to an approximately 4.2 kD protein which, in the brains of AD, Down's Syndrome, HCHWA-D and some normal aged subjects, forms the subunit of the amyloid filaments comprising the senile (amyloid) plaques and the amyloid deposits in small cerebral and meningeal blood vessels (amyloid angiopathy) .
• ⁇ AP can occur in a filamentous polymeric form (in this form, it exhibits the Congo-red and thioflavin-S dye-binding characteristics of amyloid described in connection therewith) .
• ⁇ AP can also occur in a non-filamentous form ("preamyloid” or “amorphous” or “diffuse” deposits) in tissue, in which form no detectable birefringent staining by Congo red occurs.
• preamyloid or "amorphous” or “diffuse” deposits
• Congo red form no detectable birefringent staining by Congo red occurs.
• ⁇ AP when used in connection with this invention, specifically refers to an approximately 39-43 amino acid peptide that is substantially homologous to the form of the protein produced by the method described in the patent of Glenner et al., but which, according to the instant invention, can be found in and purified from the extracellular fluid (medium) of cultured cells grown in vitro or from body fluids of humans and other mammals, including both normal individuals and individuals suffering from ⁇ AP-related conditions.
• ⁇ AP also refers to related ⁇ AP sequences that result from mutations in the ⁇ AP region of the normal gene.
• ⁇ AP is an approximately 39-43 amino acid fragment of a large membrane-spanning glycoprotein, referred to as the ⁇ - amyloid precursor protein (APP) , encoded by a gene on the long arm of human chromosome 21.
• APP ⁇ - amyloid precursor protein
• ⁇ AP is further characterized by its relative mobility in SDS-polyacrylamide gel electrophoresis or in high performance liquid chromatography (HPLC) . Its 43- amino acid sequence is:
• ⁇ AP peptides refers to intact or full length ⁇ AP as well as to fragments and degradation products of ⁇ AP which are generated at low concentrations by mammalian cells. Particular ⁇ AP fragments have a molecular weight of approximately 3 kD and are presently believed to consist of amino acid residues 11-40 and 17-40 of ⁇ AP.
• ⁇ AP junction region refers to a region of ⁇ AP which is centered at the site between amino acid residues 16 and 17 (Lys 16 and Leu 17 ) which is a target for normal proteolytic processing of APP. Such normal processing results in a variety of APP fragments which are potentially immunologically cross-reactive with the intact ⁇ AP molecule and fragments of ⁇ AP which are to be identified in the methods of the present invention.
• the junction region will span amino acid residues 10 to 35, preferably spanning amino acid residues 15 to 30, with antibodies raised against a synthetic peptide consisting of amino acid residues 13-28 having been found to display the requisite specificity.
• ⁇ -amyloid precursor protein as used herein is defined as a polypeptide that is encoded by a gene of the same name localized in humans on the long arm of chromosome 21 and that includes ⁇ AP within its carboxyl third.
• APP is a glycosylated, single-membrane-spanning protein expressed in a wide variety of cells in many mammalian tissues. Examples of specific isotypes of APP which are currently known to exist in humans are the 695-amino acid polypeptide described by Kang et al. (1987) Nature 325:733-736 which is designated as the "normal” APP; the 751-amino acid polypeptide described by Ponte et al.
• APP fragments refers to fragments of APP other than those which consist solely of ⁇ AP or ⁇ AP fragments. That is, APP fragments will include amino acid sequences of APP in addition to those which form intact ⁇ AP or a fragment of ⁇ AP.
• ⁇ AP-related condition as used herein is defined as including Alzheimer's Disease (which includes familial Alzheimer's Disease), Down's Syndrome, HCHWA-D, and advanced aging of the brain.
• conditioned culture medium and "culture medium” as used herein refer to the aqueous extracellular fluid which surrounds cells grown in tissue culture (in vitro) and which contains, among other constituents, proteins and peptides secreted by the cells.
• body fluid refers to those fluids of a mammalian host which will be expected to contain measurable amounts of ⁇ AP and ⁇ AP fragments, specifically including blood, cerebrospinal fluid (CSF) , urine, and peritoneal fluid.
• CSF cerebrospinal fluid
• blood refers to whole blood, as well as blood plasma and serum.
• ⁇ AP and ⁇ AP fragments may be detected and/or measured in a variety of biological and physiological samples, including in vitro samples, such as conditioned medium from cultured cells, including transfected cell lines and endogenous cell lines, and in vivo patient samples, typically body fluids. Detection and measurement of ⁇ AP peptides may be accomplished by any technique capable of distinguishing ⁇ AP and ⁇ AP fragments from other APP fragments which might be found in the sample. Conveniently, im unological detection techniques may be employed using binding substances specific for ⁇ AP, such as antibodies, antibody fragments, recombinant antibodies, and the like, which bind with specificity and sensitivity to ⁇ AP.
• binding substances specific for ⁇ AP such as antibodies, antibody fragments, recombinant antibodies, and the like, which bind with specificity and sensitivity to ⁇ AP.
• junction region of ⁇ AP antibodies which are monospecific for the junction region of ⁇ AP are capable of distinguishing ⁇ AP from other APP fragments.
• the junction region of ⁇ AP is centered at amino acid residues 16 and 17, typically spanning amino acid residues 13-28, and such junction-specific antibodies may be prepared using synthetic peptides having that sequence as an immunogen.
• Particularly suitable detection techniques include ELISA, Western blotting, radioimmunoassay, and the like.
• a preferred immunoassay technique is a two-site or "sandwich" assay employing a junction-specific antibody as the capture antibody (bound to a solid phase) and a second labeled antibody which binds to an epitope other than that bound to by the capture antibody.
• the second labeled antibody preferably recognizes the amino terminus of ⁇ AP and may be conveniently raised against a synthetic peptide consisting essentially of amino acid residues 1-16 of ⁇ AP.
• Particular methods for preparing such antibodies and utilizing such antibodies in an exemplary ELISA are set forth in the Experimental section hereinafter.
• ⁇ AP and ⁇ AP fragments which do not require the use of ⁇ AP specific antibodies may also be employed.
• two-dimensional gel electrophoresis may be employed to separate closely related soluble proteins present in a fluid sample.
• Antibodies which are cross-reactive with many fragments of APP, including ⁇ AP may then be used to probe the gels, with the presence of ⁇ AP being identified based on its precise position on the gel.
• the cellular proteins may be metabolically labeled and separated by SDS-polyacrylamide gel electrophoresis, optionally employing i munoprecipitation as an initial separation step. A specific example of the latter approach is described in the Experimental section hereinafter.
• Antibodies specific for the ⁇ AP may be prepared against a suitable antigen or hapten comprising the desired target epitope, such as the junction region consisting of amino acid residues 13-28 and the amino terminus consisting of amino acid residues 1-16.
• synthetic peptides may be prepared by conventional solid phase techniques, coupled to a suitable immunogen, and used to prepare antisera or monoclonal antibodies by conventional techniques.
• Suitable peptide haptens will usually comprise at least five contiguous residues within ⁇ AP and may include more than six residues.
• Synthetic polypeptide haptens may be produced by the well-known Merrifield solid-phase synthesis technique in which amino acids are sequentially added to a growing chain (Merrifield (1963) J. Am. Chem. Soc. 85:2149-2156). The amino acid sequences may be based on the sequence of ⁇ AP set forth above.
• a suitable immunogenic carrier such as serum albumin, keyhole limpet hemocyanin, or other suitable protein carriers, as generally described in Hudson and Hay, Practical Immunology, Blackwell Scientific Publications, Oxford, Chapter 1.3, 1980, the disclosure of which is incorporated herein by reference.
• An exemplary immunogenic carrier utilized in the examples provided below is ⁇ -CD3e antibody (Boehringer-Mannheim, Clone No. 145-2C11) .
• antibodies specific for the desired epitope may be produced by in vitro or in vivo techniques.
• In vitro techniques involve exposure of lymphocytes to the immunogens, while in vivo techniques require the injection of the immunogens into a suitable vertebrate host.
• Suitable vertebrate hosts are non-human, including mice, rats, rabbits, sheep, goats, and the like.
• Immunogens are injected into the animal according to a predetermined schedule, and the animals are periodically bled, with successive bleeds having improved titer and specificity.
• the injections may be made intramuscularly, intraperitoneally, subcutaneously, or the like, and an adjuvant, such as incomplete Freund's adjuvant, may be employed.
• monoclonal antibodies can be obtained by preparing immortalized cell lines capable of producing antibodies having desired specificity.
• immortalized cell lines may be produced in a variety of ways. Conveniently, a small vertebrate, such as a mouse is hyperimmunized with the desired immunogen by the method just described. The vertebrate is then killed, usually several days after the final immunization, the spleen cells removed, and the spleen cells immortalized. The manner of immortalization is not critical. Presently, the most common technique is fusion with a myeloma cell fusion partner, as first described by Kohler and Milstein (1975) Nature 256:495-497.
• ⁇ AP in patient samples can be used for diagnosing and monitoring of Alzheimer's Disease and other ⁇ AP-related conditions, such as Down's Syndrome and HCHWA-D.
• Suitable patient samples include body fluids, such as blood, CSF, urine, and peritoneal fluid.
• the presence of the ⁇ AP-related condition will generally be associated with elevated levels of ⁇ AP in the fluid when compared to those values in normal individuals, i.e., individuals not suffering from Alzheimer's Disease or any other ⁇ AP-related condition.
• Diagnostic concentrations of ⁇ AP in blood are in the range from 0.1 ng/ml to 10 ng/ml or higher, more generally 0.1 ng/ml to 3 ng/ml.
• Diagnostic concentrations of ⁇ AP in CSF are in the range from 0.1 ng/ml to 25 ng/ml or higher, more generally 0.1 ng/ml to 5 ng/ml.
• the measured concentrations of ⁇ AP may be monitored in order to follow the progress of the disease, and potentially follow the effectiveness of treatment (when such treatments become available) . It would be expected that levels of ⁇ AP would decrease with an effective treatment regimen.
• Suitable cell lines include human and animal cell lines, such as the 293 human kidney cell line, human neuroglioma cell lines, human HeLa cells, primary human endothelial cells (e.g. HUVEC cells), primary human fibroblasts or lymphoblasts, primary human mixed brain cells (including neurons, astrocytes, and neuroglia) , Chinese hamster ovary (CHO) cells, and the like.
• Preferred for use in drug screening methods according to the present invention are cell lines capable of expressing APP variants which overproduce ⁇ AP.
• overproduce it is meant that the amount of ⁇ AP produced from the variant APP will be greater than the amount produced from any or all of the normal APP isoforms, e.g., the 695, 751, and 770 amino acid isoforms which have been previously described.
• Particularly preferred are APP variants having one or several amino acid substitutions directly amino-terminal of the ⁇ AP cleavage site.
• K293 cells which express an APP DNA bearing a double mutation (Lys 595 ->Asn 595 and Met 596 ->Leu 596 ) found in a Swedish FAD family produce approximately six-to-eightfold more ⁇ AP than cells expressing normal APP.
• the mutation at residue 596 appears to be principally responsible for the increase.
• in vivo monitoring of ⁇ AP in animal models may also be used to screen compounds for therapeutic effectiveness (usually for testing of compounds which have previously been identified by an in vitro screen, such as the in vitro screen described above) .
• the test compound(s) are administered to the animal and the level of ⁇ AP or ⁇ AP fragment in a body fluid observed. Test compounds which reduce the level of the ⁇ AP in certain body fluids are considered to be candidates for further evaluation.
• test compounds can be any molecule, compound, or other substance which can be added to the cell culture without substantially interfering with cell viability. Suitable test compounds may be small molecules, biological polymers, such as polypeptides, polysaccharides, polynucleotides, and the like.
• the test compounds will typically be administered to the culture medium at a concentration in the range from about 1 nM to 1 mM, usually from about 10 ⁇ M to 1 mM. Test compounds which are able to inhibit generation, accumulation, or secretion of ⁇ AP are considered as candidates for further determinations of the ability to decrease ⁇ AP production in cells and/or animals.
• the present invention further comprises methods for inhibiting ⁇ -amyloid production in cells, where the method includes administering to the cells compounds selected by the method described above.
• the compounds may be added to cell culture in order to inhibit ⁇ AP production by the cultured cells.
• the compounds may also be administered to a patient in order to inhibit the deposition of amyloid plaque associated with Alzheimer's and other ⁇ AP-related diseases.
• the present invention further comprises pharmaceutical compositions incorporating a compound selected by the above-described method and including a pharmaceutically acceptable carrier.
• Such pharmaceutical compositions should contain a therapeutic or prophylactic amount of at least one compound identified by the method of the present invention.
• the pharmaceutically acceptable carrier can be any compatible, non-toxic substance suitable to deliver the compounds to an intended host. Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier. Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like may also be incorporated into the pharmaceutical compositions. Preparation of pharmaceutical conditions incorporating active agents is well described in the medical and scientific literature. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 16th Ed., 1982, the disclosure of which is incorporated herein by reference.
• compositions just described are suitable for systemic administration to the host, including both parenteral, topical, and oral administration.
• the pharmaceutical compositions may be administered parenterally, i.e. subcutaneously, intramuscularly, or intravenously.
• the present invention provides compositions for administration to a host, where the compositions comprise a pharmaceutically acceptable solution of the identified compound in an acceptable carrier, as described above.
• Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier.
• Indirect techniques which are generally preferred, involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxyl, carboxyl, and primary amine groups present on the drug to render the drug more lipid-soluble and amenable to transportation across the blood-brain barrier.
• the delivery of hydrophilic drugs can be enhanced by intra- arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
• the concentration of the compound in the pharmaceutical carrier may vary widely, i.e. from less than about 0.1 % by weight of the pharmaceutical composition to about 20% by weight, or greater.
• Typical pharmaceutical composition for intramuscular injection would be made up to contain, for example, one to four ml of sterile buffered water and one ⁇ g to one mg of the compound identified by the method of the present invention.
• the typical composition for intravenous infusion could be made up to contain 100 to 500 ml of sterile Ringer's solution and about 1 to 100 mg of the compound.
• the pharmaceutical compositions of the present invention can be administered for prophylactic and/or therapeutic treatment of diseases related to the deposition of ⁇ AP, such as Alzheimer's disease, Down's syndrome, and advanced aging of the brain.
• the pharmaceutical compositions are administered to a host already suffering from the disease.
• the pharmaceutical compositions will be administered in an amount sufficient to inhibit further deposition of ⁇ AP plaque.
• An amount adequate to accomplish this is defined as a "therapeutically effective dose.”
• Such effective dose will depend on the extent of the disease, the size of the host, and the like, but will generally range from about 0.01 ⁇ g to 10 mg of the compound per kilogram of body weight of the host, with dosages of 0.1 ⁇ g to 1 mg/kg being more commonly employed.
• the pharmaceutical compositions of the present invention are administered to a host susceptible to the ⁇ AP-related disease, but not already suffering from such disease.
• Such hosts may be identified by genetic screening and clinical analysis, as described in the medical literature (e.g.
• compositions will be able to inhibit or prevent deposition of the ⁇ AP plaque at a symptomatically early stage, preferably preventing even the initial stages of the ⁇ -amyloid disease.
• the amount of the compound required for such prophylactic treatment referred to as a prophylactically- effective dosage, is generally the same as described above for therapeutic treatment.
• the following examples are offered by way of illustration, not by way of limitation.
• Monoclonal antibodies to the junction region of ⁇ AP were prepared using a synthetic peptide spanning amino acid residues 13-28 ( ⁇ AP 13 _ 28 ) .
• /3AP 13 _ 28 was conjugated to an immunogen ( ⁇ -CD3e antibody; Clone No. 145-2C11, Boehringer- Mannheim) using m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) according to the manufacturer's (Pierce) instructions.
• MBS m-maleimidobenzoyl-N-hydroxysuccinimide ester
• A/J mice were immunized initially intraperitoneally (IP) with the ⁇ AP conjugate mixed with complete Freund's adjuvant.
• mice Fourteen days later, the mice were boosted IP with the ⁇ AP conjugate mixed with phosphate buffered saline (PBS) at 14 day intervals. After six total boosts, the mice were finally boosted intravenously with ⁇ AP conjugate mixed with PBS and fused 3 days later. Fusion of spleen cells with P3.653 myeloma cells was performed according as described in Oi and Herzenberg, Selective Methods in Cellular Immunology, Mishell and Shigii, Eds., W.H. Freeman and Company, San Francisco, Chapter 17 (1980) . Serum titers and initial screens were performed by the RIA method described below. Several clones were expanded to a 24 well plate and subjected to further analysis as described below. Clones of interest were produced in mouse ascites.
• PBS phosphate buffered saline
• the RIA method used to screen serum bleeds and fusion hybridoma supernatants was based upon a method developed by Wang et al. (1977) J. Immunol. Methods 18:157-164. Briefly, the supernatant (or serum) was incubated overnight at room temperature on a rotator with 125 I-labeled ⁇ AP 1 _ 28 and Sepharose® 4B beads to which sheep anti-mouse IgG had been coupled via cyanogen bromide. The beads from each well were harvested onto glass fiber filter discs with a cell harvester and washed several times with PBS. The filter discs were then transferred to gamma tubes and the bound radioactivity was counted in a gamma counter.
• the 50% inhibition point for ⁇ AP 13 _ 28 ranged from 10-80 ng/well.
• the clones were also characterized based on reactivity in Western blots. Based on titer point, sensitivity (as determined by the 50% inhibition point) , and reactivity on Western blot, several clones were produced in ascites.
• Antibodies from hybridomas designated 067, 266, 297, and 361 were selected for use as a capture antibody in the assays described below.
• ⁇ AP 1 _ 28 Monoclonal antibodies to the N-terminal region of ⁇ AP were prepared using a synthetic peptide spanning amino acid residues 1-28 ( ⁇ AP 1 _ 28 ) .
• ⁇ AP 1 _ 28 was chemically coupled using disuccimidyl suberate (DSS) to rabbit serum albumin (RSA) using a 20:1 molar ratio of peptide to protein in 50 mM sodium phosphate, pH 7.0, 150 mM NaCl, overnight at 21°C using 1 mM DSS (Hyman et al. (1992) J. Neuropath. Exp. Neuro. 51:76).
• DSS disuccimidyl suberate
• RSA rabbit serum albumin
• Antibodies 10D5 and 6C6 were obtained from a fusion where mice had received 5 injections of ⁇ AP 1 _ 28 coupled to RSA via DSS at 100 ⁇ g/ml. The initial injection was in complete Freund's adjuvant (CFA) followed by second and subsequent injections in incomplete Fruend's adjuvant (IFA) every 10-14 days. Three days before the fusion, mouse 4 which had a titer of 1/70,000 as measured by ELISA against ⁇ AP 1 _ 28 , received lOO ⁇ g of ⁇ AP 1 _ 28 RSA in PBS intraperitoneally as a final boost. Screening was done by ELISA and on paraffin-fixed AD brain sections.
• CFA complete Freund's adjuvant
• IFA incomplete Fruend's adjuvant
• the coating concentration of ⁇ AP 1 _ 28 was 1 ⁇ g/well.
• 10D5 and 6C6 were positive by ELISA and AD brain tissue section.
• Antibodies from hybridomas designated 10D5 and 6C6 were selected for use as a reporter antibody in the assays described below.
• Polyclonal Antibodies Polyclonal Antibodies . Polyclonal antibodies were raised against synthetic peptides ⁇ AP _ 38 , ⁇ AP 1 _ 40 , and ⁇ AP l - __ 2 , and were designated anti- ⁇ AP 1 _ 38 (antiserum Y) , anti- ⁇ AP 1 _ 40 (antiserum 1280) and anti- ⁇ AP 1 _ 42 (antiserum HM) . Rabbits were immunized with 0.5-3.0 mg of one of these peptides (unconjugated) in complete Freund's adjuvant intradermally.
• the rabbits received booster injections of 0.1-0.5 mg peptide 3 weeks after primary immunization and at approximately 2-4 week intervals thereafter until high titers of anti-peptide reactivity could be detected in samples of the rabbit serum. These antisera were then used in immunological assays at dilutions ranging from 1:300 to 1:1,500.
• ELISA Assay a. Binding of Capture Antibody to Microtiter Wells .
• Monoclonal antibody 266 was diluted to a concentration of 5 ⁇ g/ml, and monoclonal antibody 067 to 10 ⁇ g/ml in a buffer containing NaH 2 P0 4 '7H 2 0, 26.2 g/L; NaN 3 , 1 g/L; pH 8.3.
• One hundred ⁇ l/well of this solution was then dispensed in a 96 well polystyrene transparent COSTAR plate and incubated overnight at room temperature.
• HSA human serum albumin
• Calibrators containing known amounts of ⁇ AP and samples from various bodily or extra bodily fluids were then added to the plate at 100 ⁇ l/well.
• the samples were added undiluted or diluted in a buffer containing NaH 2 P0 4 'H 2 0, 0.2 g/L; Na 2 HP0 4 -7H 2 0, 2.16 g/L; NaN 3 , 0.5 g/L; BSA (globulin free) 6 g/L; Triton X-405, 0.5 mL/L; NaCl, 8.5 g/L; pH 7.4.
• Samples and calibrators were incubated in the wells for 1 hour at room temperature, subsequently aspirated, and the wells washed with 300 ⁇ l/well of a solution containing NaCl, 80 g/L; KC1, 3.8 g/L; Tris base, 5.85 g/L; Tris HCl, 31.75 g/L; and 0.05% Tween® 20; pH 7.5 (TBS) .
• NHS-biotin (15 mg) was dissolved in 0.25 ml dimethylsulfoxide, and 10 ⁇ l of this solution was added to 1 mg of 10D5 or 6C6 antibody suspended in 1 ml of sodium carbonate solution, 50 M, pH 8.5. The mixture was incubated in the dark for 1% hours at room temperature and then dialyzed against phosphate buffered saline, pH 7.4 for 48 hours at 4°C, to produce biotinylated reporter antibody. One hundred ⁇ l/well of the biotinylated reporter antibody (10D5 or 6C6) diluted to 3 ⁇ g/ml was then added to each well and incubated for another hour at room temperature.
• the antibody diluent consisted of Trizma base, 1.21 g/L; NaCl, 29.22 g/L; NaN 3 , 1.5 g/L, Triton X 405, 0.5 ml/L; PEG (Mw 3350), 40 g/L; Mg C1 2 '6H 2 0, 0.095 g/L; ZnCl 2 , 0.014 g/L; fetal bovine serum 100 ml/L; and BSA 2.5 g/L, pH 7.4.
• Fluorescent substrate (4-methyl-umbellipheryl phosphate in 2-amino-2-methyl propranolol buffer; pH 9.5; (100 ⁇ l/well) was added) and fluorescence read and expressed as relative fluorescent units (FSU) after 15 minutes using a Cytofluor 2300 from Millipore, with 360/40 excitation filter and 460/40 emission filter.
• K293 cells human embryonal kidney carcinoma 293 cells
• DMEM Dulbecco's modified Eagle's medium
• APP ⁇ amyloid precursor protein
• ⁇ human umbilical vein endothelial cells
• DAMI human megakaryocytoid leukemic cell line
• CHO Chinese hamster ovary
• primary human fibroblasts primary mixed brain cell cultures (including neurons, astrocytes, and icroglia) established from human or rodent brain.
• Cortical tissue (2-3 grams) was placed in 10 mis of cold HBSS to which 1 mg of DNase (Sigma Chemical Co., St. Louis, MO D3427) was added. The triturated suspension was filtered through Nitex nylon screens of 210 ⁇ m then 130 ⁇ m, as described by Pulliam et al. (1984) J. Virol. Met. 9:301. Cells were harvested by centrifugation and resuspended in neuronal medium (MEM fortified with 10% fetal bovine serum, 1% glucose, 1 mM Na pyruvate, 1 mM glutamine, 20 mM KC1) . Polyethyleneimine coated 100 mm dishes were seeded with 1.5 x 10 7 cells in 8 mis of neuronal medium. The medium was harvested and fresh medium added twice weekly. The conditioned medium from the cells (HFBC-CM) was frozen until use.
• DNase Sigma Chemical Co., St. Louis, MO D3427
• K293 cells grown under standard culture conditions underwent metabolic labeling of newly synthesized proteins by addition of 35 S-radiolabeled methionine to the culture medium.
• the medium contained no unlabeled ("cold") methionine but was otherwise identical to the standard medium used to culture K293 cells. Amounts of radioactive methionine varying from 50-300 ⁇ Ci/ml of media were used in the labeling experiments. Cells were incubated for approximately 10-20 hours. Thereafter, the medium containing any radiolabeled proteins released from the cell was collected.
• a polyclonal antibody produced to a synthetic ⁇ AP peptide comprising the amino acids Asp-1 through VaI-40 was added to the collected media and incubated for periods varying from 2-10 hours. This allowed antigen- antibody complexes to form between the anti- ⁇ AP antibody and any ⁇ AP peptide present in the culture media. Thereafter, a protein A-Sepharose® reagent capable of binding to immunoglobulins (antibodies) was added, and this mixture was further incubated for varying periods of 2-10 hours. This incubation enabled the protein A-Sepharose® beads to bind to the anti- ⁇ AP antibodies which in turn were bound to ⁇ AP peptide. The conditioned media was then centrifuged at 12,000 xg for 10 minutes to pellet the antigen-antibody-protein A- Sepharose® bead complexes.
• the immunoprecipitates of the media from metabolically labeled cells was electrophoresed on 10-20% Tris- tricine gels, which have the advantage of resolving low molecular weight proteins (such as ⁇ AP) well.
• the gels were then dried and exposed to X-ray film to produce an autoradiogram or fluorogram. Exposure times varied but were usually in the range of 2-7 days. Following development of the X-ray film, any radiolabeled proteins that were precipitated from the cell media by the anti- ⁇ AP antibody were visualized as dark bands at the appropriate molecular weight (i.e., 4 kD) .
• Antibody 266 (15 mis at 0.85 mg/ml) was dialyzed versus 10 mM Na acetate, 15 mm NaCl, pH 5.5 and then coupled to Affi-Gel® Hz Hydrazide (Bio-Rad, Richmond, CA) according to the manufacturer's protocol, using approximately 5 mis of resin. One ml of the resin was placed in a 1 x 10 cm column for the purification of ⁇ AP from 4 liters of conditioned medium.
• the Swedish mutation involves two adjacent base pair conversions: nucleotide 1785 G to T and nucleotide 1786 A to C which leads to two amino acid exchanges: Lys->Asn 595 and Met->Leu 596 (all numbering based on APP 695 ) .
• This primer contains a Bglll restriction endonuclease site (AGA TCT) corresponding to the Bglll site in position 1770 of APP and contains the two described nucleotide exchanges at positions 24 and 25 of the primer.
• Primer 2 (anti-sense) is a 29-mer with the sequence AAT CTA TTC ATG CAC TAG TTT GAT ACA ' GC.
• the primer contains a Spel restriction endonuclease site (ACT AGT) corresponding to position 2360 of APP.
• ACT AGT Spel restriction endonuclease site
• Bglll and Spel were chosen as they are both single cut sites in this vector and therefore allow the simple removal of the non-mutated restriction fragment corresponding to the fragment created by PCR. Accordingly the approximately 600 basepair vector fragment was replaced by the PCR generated fragment of equal length carrying the mutation by standard techniques.
• DNA of recombinant bacterial clones was obtained by standard methods which was screened for the absence of an Mbo II restriction endonuclease site. Then the DNA sequence was confirmed by sequencing of the complete region that had undergone the PCR reaction.
• the ⁇ AP ELISA assay was used to detect known amounts of synthetic ⁇ AP peptides ⁇ AP 1 _ 38 and ⁇ AP 1 _ 40 .
• the assay employing 266 capture antibody and 10D5 reporter antibody was able to detect the peptides at 0.1 ng/ml. See Fig. 1.
• the 266/10D5 assay was found not to significantly cross-react with full length APP, secreted APP 695 or 751, recombinant APP fragments constructs 15 or 6, ⁇ AP fragments 15- 20, 11-18, 13-18, or 13-20, or fibrinogen (Table I).
• the ELISA assay was used to screen blood and CSF samples from humans, dogs, guinea pigs, and rats. Detectable amounts of ⁇ AP were found, with concentrations in the ranges set forth in Table II.
• C normal individuals
• AD patients cerebrovascular accident
• PD Parkinson's Disease
• the rest of the control individuals had a variety of non-AD neuronal degenerative diseases.
• the AD mean values are well above the control pool value.
• polyclonal antibody 1280 immunoprecipitated a 4 kD protein from K293 cell media that comigrated precisely with a standard sample of radioiodinated synthetic ⁇ AP 1 _ 40 peptide.
• a 3 kD protein was simultaneously precipitated. This appears to be a fragment of ⁇ AP lacking the first 10 or 16 amino acids.
• the 1280 antibody was preabsorbed with synthetic ⁇ AP 1 _ 40 peptide to block its activity, no 3 kD or 4 kD bands were precipitated from the K293 cell media.
• the preimmune sera i.e., a sample of normal serum taken from each rabbit used to raise the polyclonal antibodies prior to the actual immunization
• other antibodies to regions of APP flanking the ⁇ AP region were used in the above immunoprecipitation/autoradiography assay. For example, an antibody to the 20-amino acid region immediately amino-terminal to the beginning of the ⁇ AP region of APP failed to precipitate the 4 kD peptide from media.
• Immunoprecipitation/autoradiography showed an increased amount of precipitable 4 kD protein in the media of the transfected versus non-transfected cells, as expected from their increased production of the APP precursor molecule. See Fig. 5.
• the media of the transfected cells showed more of the APP S soluble fragment of APP than the media of the non- transfected cells; this positive control reaction was observed simultaneously in the immunoprecipitates that contained the 4 kD protein.
• the same result was obtained when a different cell type, Chinese hamster ovary (CHO) cells, was used. Comparison of CHO cells either untransfected or transfected with APP cDNA showed increased levels of the 4 kD 1280-precipitable peptide in the media of the latter cells.
• ⁇ AP native ⁇ AP was extracted from autopsied human cerebral cortex of patients who died with AD. This sample of A ⁇ from AD brain tissue comigrated with the 4 kD 1280-precipitable peptide from cultured cell media when analyzed by SDS-polyacrylamide gel electrophoresis. This comigration provided further support for the identity of the 4 kD peptide as ⁇ AP.
• Four liters of human fetal brain culture-conditioned media (HFBC-CM) were thawed and filtered through a 0.45 ⁇ m filtering flask.
• Leupeptin (1 ⁇ g/ml) and PMSF (35 ⁇ g/ml) taken from a 35 mg/ml stock in isopropanol were added to the HFBC-CM immediately prior to affinity chromatography.
• the material was run through the 266-affinity column at a flow rate of approximately 2 ml/min at 4°C.
• the column was then washed with 500 mis of PBS. Elution of material specifically bound to the resin was achieved with 0.2 M glycine pH 2.0. A total of 9 mis was used.
• the eluted material was subjected to two steps of reversed phase liquid chromatography using a Vydac C4 [0.21 x 15 cm] reversed phase column and a solvent system containing 0.1% TFA in buffer "A” and 0.1% TFA/80% acetonitrile in buffer "B".
• the affinity-purified material was loaded onto the reversed phase column at 200 ⁇ l/min and then washed with 80% buffer (A) and 20% buffer "B” at 200 ⁇ l/min for 60 min and 50 ⁇ l/min for 42 min to equilibrate the column and stabilize the baseline.
• a gradient from 20% to 70% "B” was executed over 50 min at 50 ⁇ l/min, and the eluant was monitored at 0D 220'
• Fractions of 100 ⁇ l were collected and assayed by both Western blot and ELISA. Based on these results, fractions 11 and 12 were pooled and rechromatographed under nearly identical conditions except that a 150 min gradient from 10 to 40% "B” was employed followed by a 20 min gradient from 40 to 100% "B”. Fraction 77 from the second reversed phase chromatography step was found to be reactive against the 10D5 antibody by both Western blot (Fig. 4) and ELISA.
• Fractions 65 and 70 contained an additional sequence of a previously undescribed ⁇ AP fragment beginning at ⁇ AP residue 11 (Glu) .
• fraction 65 sufficient material was present to sequence through ⁇ AP residue 33.
• Lane 12 was buffer only; lane 13 contained 20 ng of ⁇ AP 1-38; lane 14 contains 100 ng of ⁇ AP 1-38; lane 15 contains low molecular weight Rainbow® standards (Amersham) . Note the approximate 4 kD band in lane 6 which co-migrates with the ⁇ AP standard in lane 14.
• Sequencing data confirmed the presence of N-terminal sequences beginning with ⁇ AP residue 1 (Asp) and ⁇ AP residue 11 (Glu) .
• ELISA for APP S used polyclonal antibodies B5 and B3. For each ELISA, increasing amounts of purified synthetic ⁇ AP- j ⁇ Q or purified APP S from conditioned media of K293 cells transfected with cDNA for the APP 695 isoform were used to construct a standard curve. Quantitation of ⁇ AP (left panel) and APP S (right panel) in conditioned media in the transiently transfected K293 cells is shown in Fig. 7. Each column represents the mean of four transfections with the exception of the mock column, which is based on three cultures. Error bars indicate the standard deviation. For columns without error bars, the standard deviation was less than 0.01 units. As shown in Fig.
• cells expressing the Swedish variant APP 695 construct produced 6-7 fold more ⁇ AP in their media than identically transfected cells expressing normal APP (695 isoform) . Moreover, a similar 7-8 fold increase was observed in cultures expressing the Swedish mutation in the APP 751 isoform (Fig. 7) . Similar increases in ⁇ AP levels were documented using a second method of quantitation: phosphor i ager analysis of the 4 kD ⁇ AP band in gels of 1280 immunoprecipitates. This method further demonstrated that the 3 kD fragment was decreased several fold in the media of the Swedish transfectants. CHO and K293 cells stably transfected with cDNA the Swedish mutation in the APP 751 isoform also showed marked increases in the levels of ⁇ AP in their cultured media.
• Fig. 8 shows conditioned media of radiolabeled K293 cells transiently transfected with no DNA (lane 1) ; normal APP (lane 2) , Swedish mutant APP 695 KM-NL (lane 3), variant APP 695 K-N (lane 4), variant APP 695 M-L (lane 5) , APP ⁇ C (APP cytoplas ic domain deletion, lane 6) and APP ⁇ C KM-NL (Swedish mutations and cytoplasmic domain deletions, lane 7) and immunoprecipitated with 1280.
• the ⁇ AP and 3 kD bands are indicated by arrows.
• 125 I-labeled synthetic ⁇ AP (1-40) was run as a size marker on the same gel (lane 8) .
• Cells expressing the Met->Leu substitution had increased levels of ⁇ AP in their medium, whereas cells expressing the Lys->Asn substitution had levels similar to normal transfectants (Fig. 8, lanes 2-5).
• This finding suggests that the 596 mutation results in more proteolytic cleavage of APP at the Leu-Asp peptide bond than at the normal Met-Asp bond. It is possible that the Lys->Asn switch at 595 may further enhance the cleavage when coupled with the Met->Leu substitution at 596.
• Two cell lines (human kidney cell line K293 and Chinese hamster ovary cell line (CHO) were stably transfected with gene for APP751 containing the double mutation Lys-651-Met-652 to Asn651-Leu-652 (APP-751 numbering) commonly called the Swedish mutation using the method described in Citron et al. (1992) Nature 360:672-674.
• the transfected cell lines were designated as 293 751 SWE and CHO 751 SWE, and were plated in Corning 96 well plates at 2.5X10 4 cells per well respectively in Dulbecco's minimal essential media plus 10% fetal bovine serum.
• Protease inhibitor stocks were prepared in DMSO such that at the final concentration used in the treatment, the concentration of DMSO did not exceed 0.5%
• plates were centrifuged in a Beck an GPR at 1200 rpm for five minutes at room temperature to pellet cellular debris from the conditioned media. From each well, 100 ⁇ l of conditioned media were transferred into an ELISA plate precoated with antibody 266 against ⁇ AP-13-28 as described above and stored at 4°C overnight.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Neurology (AREA)
• General Health & Medical Sciences (AREA)
• Neurosurgery (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Psychiatry (AREA)
• Veterinary Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Public Health (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Food Science & Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Toxicology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (2)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (3)

Family

ID=25510753

Family Applications (2)

Family Applications After (1)

Country Status (9)

Families Citing this family (53)

Citations (1)

Family Cites Families (6)

• 1993
  • 1993-09-01 JP JP51104194A patent/JP3553592B2/ja not_active Expired - Lifetime
  • 1993-09-01 AT AT93921300T patent/ATE247282T1/de not_active IP Right Cessation
  • 1993-09-01 PT PT02079139T patent/PT1298436E/pt unknown
  • 1993-09-01 WO PCT/US1993/008264 patent/WO1994010569A1/fr active IP Right Grant
  • 1993-09-01 DE DE69333144T patent/DE69333144T2/de not_active Revoked
  • 1993-09-01 DE DE69334337T patent/DE69334337D1/de not_active Expired - Lifetime
  • 1993-09-01 DK DK93921300T patent/DK0667959T3/da active
  • 1993-09-01 PT PT93921300T patent/PT667959E/pt unknown
  • 1993-09-01 EP EP93921300A patent/EP0667959B1/fr not_active Revoked
  • 1993-09-01 AT AT02079139T patent/ATE474224T1/de active
  • 1993-09-01 DE DE0667959T patent/DE667959T1/de active Pending
  • 1993-09-01 DK DK02079139.8T patent/DK1298436T3/da active
  • 1993-09-01 ES ES93921300T patent/ES2203620T3/es not_active Expired - Lifetime
  • 1993-09-01 ES ES02079139T patent/ES2346852T3/es not_active Expired - Lifetime
  • 1993-09-01 EP EP02079139A patent/EP1298436B1/fr not_active Expired - Lifetime
  • 1993-09-10 CA CA2105903A patent/CA2105903C/fr not_active Expired - Lifetime
• 2003
  • 2003-10-02 JP JP2003344850A patent/JP3694303B2/ja not_active Expired - Lifetime

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events